Effect of Radium-223 Dichloride on Hospitalization for Symptomatic Prostate Cancer Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Effect of Radium-223 Dichloride (Ra-223) on Hospitalisation: An Analysis From the Phase 3 Randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) Trial
Eur. J. Cancer 2017 Jan 01;71(xx)1-6, C Parker, L Zhan, P Cislo, J Reuning-Scherer, NJ Vogelzang, S Nilsson, O Sartor, JM O'Sullivan, RE ColemanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.